Even phII results aren't worth a lot when it comes to partnering unless they are really exceptional. The big pharma sector is a cut throat area. I hold Alchemia as well, with 3 Ph1, 3 Ph2 and 1 ph3 all but complete in pretty big money areas and we are still being priced at <$200m mc including an income stream of $10m pa from a generic we designed.
A completed ph3 is an entirely different matter as the product is de-risked. Ph1's have little value at all, but this one, with Professor Frazer's name attached should generate more interest than usual. I wouldn't like to see them partner on it though. Stunning results from a ph2 and I wouldn't mind as ph3 completion will be 3 years off I reckon.
- Forums
- ASX - By Stock
- AVR
- Nice finish
Nice finish, page-54
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$17.79 |
Change
-0.120(0.67%) |
Mkt cap ! $347.9M |
Open | High | Low | Value | Volume |
$18.00 | $18.10 | $17.79 | $30.95K | 1.724K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 26 | $17.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.90 | 162 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 26 | 17.720 |
1 | 560 | 17.710 |
1 | 443 | 17.700 |
2 | 276 | 17.650 |
1 | 200 | 17.560 |
Price($) | Vol. | No. |
---|---|---|
17.900 | 162 | 3 |
17.930 | 120 | 1 |
17.950 | 200 | 1 |
18.140 | 45 | 1 |
18.240 | 500 | 1 |
Last trade - 11.28am 16/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online